The new framework removes the requirement for coverage with evidence determination (CED) for TAVR in patients with symptomatic severe aortic valve stenosis and extends coverage to asymptomatic aortic ...

The Centers for Medicare and Medicaid Services (CMS) coverage with evidence development (CED) program provides coverage for items and services not meeting Medicare’s “reasonable and necessary” ...

For 14 years, patient access to TAVR has been restricted for Medicare beneficiaries under a Coverage with Evidence ...

The proposed Medicare coverage change could help Edwards Lifesciences gain market share from Medtronic and Boston Scientific, an analyst said.

In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...

The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a draft coverage memo for cardiac contractility modulation (CCM), which offers coverage with evidence development for the company’s ...

CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of symptomatic tricuspid regurgitation. The procedures will be subject to CMS ...

The recent decision by the US Centers for Medicare and Medicaid Services (CMS) to cover tricuspid transcatheter edge-to-edge repair (T-TEER) could help change the model through which physicians think ...